Business Highlights

The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues - and looming competition threatens its near-monopoly. Mylan N.V. has faced intense criticism for hiking the price for the potentially life-saving drug more than 500 percent after acquiring the product in 2007.